盐酸咪达唑仑(Midazolam Hydrochloride) - 药物靶点：GABAA receptor_在研适应症：癫痫持续状态，麻醉，癫痫发作_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Midazolam hydrochloride (USAN)、Ozalin、NSC-751451

+ [9]

靶点

GABAA receptor

作用方式

激动剂

作用机制

GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

癫痫持续状态麻醉癫痫发作+ [1]

非在研适应症-

原研机构

F. Hoffmann-La Roche Ltd.

在研机构

Neuraxpharm Pharmaceuticals S.L.

Rafa Laboratories Ltd.

江苏恩华药业股份有限公司

+ [2]

非在研机构

Shire Plc

Meridian Medical Technologies LLCHoffmann-La Roche, Inc.

权益机构

Nordic Pharma Group

Takeda Pharmaceutical Co., Ltd.

Neuraxpharm

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1985-12-20),

麻醉镇静

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C18H14Cl2FN3

InChIKeyPLYSCVSCYOQVRP-UHFFFAOYSA-N

CAS号59467-96-8

关联

799

项与盐酸咪达唑仑相关的临床试验

NCT05945147

/ Withdrawn临床2期IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

开始日期2099-01-01

申办/合作机构

Stanford University

NCT06692192

/ Recruiting临床1期IIT

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.
Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.
Participants will:
* Receive one of four possible combinations of medications
* Undergo an MRI
* Complete questionnaires
* Undergo transcranial magnetic stimulation (TMS) and EEG

开始日期2025-08-01

申办/合作机构

University of Wisconsin Madison

NCT07095842

/ Not yet recruiting临床2/3期IIT

Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status Epilepticus

The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.

开始日期2025-08-01

申办/合作机构

Sohag University

100 项与盐酸咪达唑仑相关的临床结果

登录后查看更多信息

100 项与盐酸咪达唑仑相关的转化医学

登录后查看更多信息

100 项与盐酸咪达唑仑相关的专利（医药）

登录后查看更多信息

10,014

项与盐酸咪达唑仑相关的文献（医药）

2025-09-01·BIOMATERIALS

Bioprinted high cell density liver model with improved hepatic metabolic functions

Article

作者: Feng, Gen-Sheng ; Meng-Saccoccio, Tobias ; Lu, Ting-Yu ; Xiang, Yi ; Chen, Shaochen ; Sun, Yazhi ; Shen, Erin Nicole ; Lyu, Cheng ; Ji, Yichun

In vitro liver tissue models are valuable for studying liver function, understanding liver diseases, and screening candidate drugs for toxicity and efficacy. While three-dimensional (3D) bioprinting shows promise in creating various types of functional tissues, current efforts to engineer a functional liver tissue face challenges in replicating native high cell density (HCD) and maintaining long-term cell viability. HCD is crucial for establishing the cell-cell interactions necessary to mimic the liver's metabolic and detoxification functions. However, HCD bioinks exacerbate light scattering in light-based 3D bioprinting. In this study, we incorporated iodixanol into our bioink formulation to minimize light scattering, enabling the fabrication of hepatic tissue constructs with an HCD of 8 × 10⁷ cells/mL while maintaining high cell viability (∼80 %). The printed dense hepatic tissue constructs showed enhanced cell-cell interactions, as evidenced by increased expression of E-cadherin and ZO-1. Furthermore, these constructs promoted albumin secretion, urea production, and P450 metabolic activity. Additionally, HCD hepatic tissue inactivated the YAP/TAZ pathway via cell-cell interactions, preserving primary hepatocyte functions. Further screening revealed that hepatocytes in the dense model were more sensitive to drug treatments than those in a lower-density hepatic model, highlighting the importance of HCD in recapitulating the physiological drug responses. Overall, our approach represents a significant advancement in liver tissue engineering, providing a promising platform for the development of physiologically relevant in vitro liver models for drug screening and toxicity testing.

2025-08-01·EPILEPSY RESEARCH

Adequate and inadequate dosing of anti-seizure medications in status epilepticus

Article

作者: Smith, Melissa ; Schrader, Susan

BACKGROUND:

Status epilepticus (SE) is defined as five or more minutes of continuous seizures or two or more discrete seizures with incomplete recovery of consciousness.¹ The incidence of SE in the United States ranges from 18.3 to 41 per 100,000 patients per year². Reviews of SE clinical literature demonstrate that 70-75 % of patients did not receive an adequate dose of benzodiazepine according to clinical guidelines. Underdosing of benzodiazepines increases the risk of refractory SE and unfavorable outcomes.^8-9 METHODS: This single center retrospective cohort study evaluated the dosing of benzodiazepines and other anti-seizure medications in adult patients with SE. The primary outcomes were incidence of breakthrough seizures in patients with appropriate dosing benzodiazepines compared to inappropriate dosing of benzodiazepines within 24 h of the first dose and incidence of breakthrough seizures in patients with appropriate loading dose of maintenance anti-seizure medication compared to inappropriate loading dose of anti-seizure medication within 24 h of the first dose.

RESULTS:

Thirty-eight patients received adequate benzodiazepine dosing compared to 155 with inadequate dosing. Eighty-seven percent of patients with adequate dosing of benzodiazepine experienced a breakthrough seizure compared to 84 % of patients with inadequate dosing (p = 0.62). Sixty-three percent of patients with adequate dosing of benzodiazepines required first non-benzodiazepine anti-seizure medication compared to 63 % of patients with inadequate dosing (p = 0.76). Breakthrough seizures within 24 h after the first load of non-benzodiazepine anti-seizure medication occurred in 21 % of patients in the adequate dosing group compared to 28 % in the inadequate dosing group (p = 0.73).

CONCLUSION:

While benzodiazepines and rescue anti-seizure medications are frequently underdosed in patients with status epilepticus, there was no difference in recurrent seizures comparted to those with adequate dosing.

2025-08-01·CHEMICO-BIOLOGICAL INTERACTIONS

A genetic algorithm-based approach for quantitative prediction of drug-drug interactions caused by cytochrome P450 3A inhibitors and inducers in dogs and cats

Article

作者: Di Paolo, Veronica ; Dacasto, Mauro ; Quintieri, Luigi ; Poggesi, Italo ; Ferrari, Francesco Maria ; Capolongo, Francesca

A genetic algorithm (GA)-based framework was developed to predict drug-drug interactions (DDIs) caused by cytochrome P450 3A (CYP3A) inhibition or induction in dogs and cats. Area under the plasma concentration-time curve (AUC) ratios, obtained from published in vivo DDI studies, were used to calculate the following parameters: (a) the contribution ratio (CR), which represents the fraction of the dose of the victim drug metabolized via CYP3A, and (b) the inhibitory potency (inhibition ratio; IR) or inducing potency (IC) of the perpetrator drug. AUC ratios of 3 substrates, 4 inhibitors and 1 inducer of CYP3A in cats, and the AUC ratios of 10 substrates, 12 inhibitors and 3 inducers of CYP3A in dogs were successfully predicted and validated by the developed methodology within 50-200 % of observed values. This approach could represent a useful resource to predict the extent of DDIs in clinical scenarios requiring the simultaneous administration of a CYP3A substrate drug with a CYP3A perpetrator.

16

项与盐酸咪达唑仑相关的新闻（医药）

2025-07-14

·GlobeNewswire-Health Care

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“EGFR”) and anaplastic lymphoma kinase (“ALK”) inhibitors for the treatment of non-small cell lung cancer (“NSCLC”) are substrates of the Cytochrome P450 (“CYP”) enzyme CYP3A, and therefore their combination with drugs that are strong inducers of CYP3A is to be avoided, or is contraindicated. As per the International Council for Harmonization (“ICH”) M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor of CYP3A; these results support the combination strategy of NXP900 with EGFR/ALK Inhibitors in NSCLC and potentially additional combinations. July 08, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the successful completion of a clinical DDI study in healthy volunteers for NXP900, supporting NXP900’s potential as a combination partner with leading therapies. Key Study Objective: To determine whether NXP900 is an inducer of CYP3A, and if so, to classify its induction as weak, moderate or strong as per ICH M12 guidelines Study Population: 14 healthy volunteers Key Pharmacokinetics Result: NXP900 increased the concentration of Midazolam, a known CYP3A sensitive substrate, by Key Safety Results: No serious or severe adverse events were reported in this study; diarrhea and non-infection related increases in white blood cell counts were the most common adverse events reported, all mild to moderate in intensity Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “As we’re now completing the dose escalation Phase 1a study of NXP900 in patients with advanced cancers, the data generated to date, including the preclinical and mechanistic data, the clinical safety, pharmacokinetics and pharmacodynamics data, and now the clinical DDI data, strongly support advancing NXP900 into the Phase 1b program, set to begin in the coming weeks. In the Phase 1b we plan to test the therapeutic potential of NXP900 as a single agent and in non-chemotherapy based combinations with leading EGFR and ALK drugs in patients that may derive substantial clinical benefit from treatment with NXP900, as their cancers are expected to be sensitive to inhibition of SRC/YES1.” Mr. Bentsur concluded, “We believe that NXP900’s differentiating properties, mainly the type 1.5 mechanism of action which combines potent and selective inhibition of both the kinase activity and scaffolding properties of the SRC family kinases, should translate into a wide therapeutic window, and we are excited about the future of NXP900.” Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. The content above comes from the network. if any infringement, please contact us to modify.

临床研究

2025-01-07

·PRNewswire

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support market entry into new territories including Australia BARCELONA, Spain and DÜSSELDORF, Germany, Jan. 7, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end of December 2024 Provigil® (modafinil) and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe, with significant sales in France, Spain and Italy. Nuvigil is present in international markets with significant sales in Australia and Mexico. Both Provigil and Nuvigil are orally administered CNS stimulants indicated to improve wakefulness and reduce Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy, both with and without cataplexy. This acquisition is in line with Neuraxpharm's strategy to grow strong CNS brands and bring them to increasing numbers of patients worldwide. It will enable entry into new territories such as Australia, where Neuraxpharm also plans to launch first-in-class multiple sclerosis treatment ublituximab (BRIUMVI®), and will furthermore reinforce Neuraxpharm's presence in Mexico, where the Company established an office in 2023. The transaction follows the acquisition from Sanofi of two established product portfolios in 2023 and the securing of a landmark partnership with TG Therapeutics also in 2023 to commercialise ublituximab outside the US*. In 2020, Neuraxpharm acquired market-leading child epilepsy treatment Buccolam® (oromucosal midazolam) from Takeda, and in September last year Neuraxpharm received a positive CHMP opinion from the European Medicine Agency to extend Buccolam's indication to include the treatment of epilepsy in adults. Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "Today's acquisition is an example of how Neuraxpharm can harness its neurology-focused approach, broad international platform and entrepreneurial capabilities to expand strong CNS brands. These two leading narcolepsy treatments will be added to our broad and growing CNS portfolio. We will leverage our specialisation and reach to grow these products in existing and new markets, thereby bringing market-leading treatments to more CNS patients with unmet needs around the world." No financial details of the transaction have been disclosed. ^ Republic of Korea, Japan, Thailand and the United States are not included in this acquisition. * Territories outside the United States, Canada, Mexico, and excluding certain Asian countries previously partnered. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has c.1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit SOURCE Neuraxpharm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准并购临床结果

2023-02-27

·米内网

【获批】江苏药企发力，拿下9亿麻醉剂首家过评

精彩内容近日，江苏恩华药业发布公告称，控股子公司江苏远恒药业的依托咪酯中/长链脂肪乳注射液获批上市，该产品按4类仿制获批视同过评。依托咪酯是一款畅销麻醉剂，2021年在中国公立医疗机构终端销售额超过9亿元。公告中提到，依托咪酯中/长链脂肪乳注射液用于全身麻醉诱导：成人、6个月以上婴幼儿、儿童和青少年。图1：目前已上市的依托咪酯制剂来源：米内网新版数据库米内网数据显示，目前已上市的依托咪酯制剂主要为注射剂，恩华药业、恒瑞医药以及贝朗三足鼎立，本次获批的依托咪酯中/长链脂肪乳注射液为该品种首个过评产品。图2：依托咪酯注射剂的销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，依托咪酯在2013-2021年的销售额均保持正增长态势，2021年达到峰值9.7亿元，2022上半年增速为6.06%，江苏恩华药业以超过90%的市场份额领军。表1：江苏恩华药业已过评（含视同过评）的产品来源：米内网中国申报进度（MED）数据库截至2月24日，江苏恩华药业已过评（含视同过评）的产品达18个，枸橼酸舒芬太尼注射液、利培酮分散片、氯氮平片、氯硝西泮片、咪达唑仑注射液、盐酸咪达唑仑口服溶液、依托咪酯中/长链脂肪乳注射液（按产品名统计）为首家过评。资料来源：NMPA官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2月24日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与盐酸咪达唑仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00696	盐酸咪达唑仑	N05CD08	DB00683

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
癫痫持续状态	美国	Meridian Medical Technologies LLC	2018-09-14
癫痫发作	欧盟	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	冰岛	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	列支敦士登	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
癫痫发作	挪威	Neuraxpharm Pharmaceuticals S.L.	2011-09-04
麻醉	美国	Hoffmann-La Roche, Inc.	1985-12-20
镇静	美国	Hoffmann-La Roche, Inc.	1985-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05610969 (CTgov)	临床1/2期	表现焦虑 \| 神经阻滞 \| 焦虑症	36	Music (Music Group)	醖網廠醖衊鬱蓋製繭積(襯願襯襯鹽構膚齋廠願) = 製廠鬱積繭淵夢鏇餘夢製鏇襯選鏇蓋願艱齋鑰 (積壓餘鹽鹽窪衊壓糧醖, 7.02) 更多	-	2025-05-14
				Midazolam (Midazolam Group)	醖網廠醖衊鬱蓋製繭積(襯願襯襯鹽構膚齋廠願) = 廠餘憲遞鏇構鹽願廠醖製鏇襯選鏇蓋願艱齋鑰 (積壓餘鹽鹽窪衊壓糧醖, 9.22) 更多
NCT04068948 (CTgov)	临床4期	镇静 \| 龋齿	37	Meperidine+Midazolam+Hydroxyzine (Midazolam, Hydroxyzine, Meperidine)	膚糧顧遞淵艱構壓獵壓 = 構膚觸鹹鬱鹽願積鏇繭鹽積廠衊蓋淵觸鹽鹽範 (齋襯鬱選鏇簾網築襯構, 餘鑰積夢餘醖齋顧築鹹 ~ 淵壓廠廠願膚夢鑰壓獵) 更多	-	2023-12-05
				Midazolam+Hydroxyzine (Midazolam, Hydroxyzine)	膚糧顧遞淵艱構壓獵壓 = 蓋遞齋壓窪構遞簾淵鹹鹽積廠衊蓋淵觸鹽鹽範 (齋襯鬱選鏇簾網築襯構, 憲艱齋醖衊積願獵簾鹽 ~ 憲網積膚遞築淵積夢構) 更多
NCT02856698 (MIMO, CTgov)	临床4期	急性肺水肿	111	Midazolam (Midazolam)	窪簾夢壓繭鹽顧鑰構壓 = 淵壓願鹹獵餘簾鬱壓蓋糧醖膚餘觸鏇餘鏇鹽蓋 (鑰襯窪積艱鬱醖淵網憲, 鏇衊築鬱廠鹽衊鬱淵醖 ~ 網壓製艱餘範餘遞遞顧) 更多	-	2022-05-19
				Morphine (Morphine)	窪簾夢壓繭鹽顧鑰構壓 = 膚觸網築壓廠齋製範鬱糧醖膚餘觸鏇餘鏇鹽蓋 (鑰襯窪積艱鬱醖淵網憲, 鏇夢艱衊顧廠製遞襯壓 ~ 壓鑰鏇糧鏇廠蓋廠構膚) 更多
NCT03085563 (CTgov)	临床4期	脓肿 \| 镇静 \| 撕裂	63	Nitrous Oxide (Nitrous Oxide)	構遞願遞夢構築膚醖繭(鑰簾糧選願構製鏇範構) = 顧衊廠蓋艱願衊構淵顧窪鹽積積獵鏇鑰壓夢醖 (獵繭製鹹醖齋獵顧夢膚, 夢艱餘鏇繭淵廠遞膚願 ~ 範蓋構鬱憲願餘膚蓋鏇) 更多	-	2022-05-10
				Midazolam (Intranasal Midazolam)	構遞願遞夢構築膚醖繭(鑰簾糧選願構製鏇範構) = 顧襯齋膚觸齋繭選壓鑰窪鹽積積獵鏇鑰壓夢醖 (獵繭製鹹醖齋獵顧夢膚, 壓蓋積膚範鹹廠餘願醖 ~ 廠獵膚顧齋獵蓋獵窪鹹) 更多
NCT03336450 (CTgov)	临床3期	癫痫持续状态	3	MHOS/SHP615	範鹽積憲製廠鑰簾積餘 = 選鏇鹽鑰顧蓋夢餘構構蓋糧觸遞淵淵夢遞鬱夢 (餘網積艱夢築築壓夢廠, 積顧窪願簾鬱鑰憲窪願 ~ 衊壓蓋製願夢壓鹹鏇衊) 更多	-	2021-09-14
NCT02356705 (CTgov)	临床4期	镇静	42	saline placebo (Saline Placebo)	衊蓋積夢積窪齋壓鑰糧 = 壓積鏇糧網壓醖範製觸鏇鹽構積壓積範醖鏇遞 (遞鏇繭遞鑰願夢鹹鹽襯, 膚繭襯遞遞選鹹遞鑰鏇 ~ 築顧願獵衊築廠網餘壓) 更多	-	2021-02-25
				Midazolam (Nasal Midazolam Only)	衊蓋積夢積窪齋壓鑰糧 = 鬱積廠選糧窪襯餘淵繭鏇鹽構積壓積範醖鏇遞 (遞鏇繭遞鑰願夢鹹鹽襯, 製鹽鬱醖膚選願衊夢齋 ~ 壓鏇鬱艱憲衊製鹹繭顧) 更多
NCT02486328 (CTgov)	临床4期	胃肠功能紊乱 \| 认知	103	Meperidine+Midazolam (Group MM)	積鹹廠鬱積簾獵網繭鬱(願襯獵願顧鑰蓋觸憲構) = 觸淵膚衊艱夢蓋獵壓獵獵鹹蓋簾壓鑰顧積繭鑰 (鏇構鏇範願窪簾餘顧衊, 10.6) 更多	-	2020-09-03
				Propofol+Remifentanil (Group RP)	積鹹廠鬱積簾獵網繭鬱(願襯獵願顧鑰蓋觸憲構) = 醖醖鹽鬱積選餘積構獵獵鹹蓋簾壓鑰顧積繭鑰 (鏇構鏇範願窪簾餘顧衊, 6.8) 更多
NCT03246724 (CTgov)	临床4期	镇静	327	Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Cataract Procedures)	鑰鬱獵艱襯鹽鑰鹹廠齋(膚襯製積鹹醖餘築鑰醖) = 齋願範鏇窪網鹽憲蓋蓋簾夢願淵衊醖製膚網鹽 (壓鏇遞範製廠鹽衊積築, 0.57) 更多	-	2020-08-19
				Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Retina Procedures)	鑰鬱獵艱襯鹽鑰鹹廠齋(膚襯製積鹹醖餘築鑰醖) = 蓋鹹糧網襯鑰積範遞鑰簾夢願淵衊醖製膚網鹽 (壓鏇遞範製廠鹽衊積築, 0.72) 更多